Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

September 27, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB 3235-0287 Number:

January 31, 2005

0.5

Expires: Estimated average

burden hours per

response...

subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **BROWN MICHAEL S**

(First)

(Middle)

2. Issuer Name and Ticker or Trading

Symbol

REGENERON

PHARMACEUTICALS INC

[REGN]

3. Date of Earliest Transaction

(Month/Day/Year) 09/25/2013

(Check all applicable)

_X__ Director Officer (give title

5. Relationship of Reporting Person(s) to

10% Owner Other (specify

777 OLD SAW MILL RIVER ROAD

(Last)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

Issuer

TARRYTOWN, NY 10591

(City)	(State)	(Zip) Tabl	e I - Non-D	erivative	Secur	ities Acqui	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi n(A) or Di (Instr. 3,	(A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/25/2013		M(1)	5,000	A	\$ 33.42	19,662	D	
Common Stock	09/25/2013		S(1)	2,300	D	\$ 292.6 (2)	17,362	D	
Common Stock	09/25/2013		S <u>(1)</u>	1,200	D	\$ 294.09 (3)	16,162	D	
Common Stock	09/25/2013		S <u>(1)</u>	1,400	D	\$ 294.81	14,762	D	

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

					(4)		
Common Stock	09/25/2013	S(1)	100	D	\$ 296	14,662	D
Common Stock	09/26/2013	M <u>(1)</u>	5,000	A	\$ 33.42	19,662	D
Common Stock	09/26/2013	S <u>(1)</u>	5,000	D	\$ 309	14,662	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number omf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Shares
Non-Qualified Stock Option (right to buy)	\$ 33.42	09/25/2013		M <u>(1)</u>	5,000	<u>(5)</u>	01/03/2021	Common Stock	5,00
Non-Qualified Stock Option (right to buy)	\$ 33.42	09/26/2013		M <u>(1)</u>	5,000	<u>(5)</u>	01/03/2021	Common Stock	5,00

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
BROWN MICHAEL S								
777 OLD SAW MILL RIVER ROAD	X							
TARRYTOWN, NY 10591								

Reporting Owners 2

Relationshine

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Signatures

/s/**Michael S.

Brown 09/26/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 2,300 shares of Company stock on September 25, 2013 at prices ranging from (2) \$292.46 to \$293.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 25, 2013 at each separate price.
- Represents volume-weighted average price of sales of 1,200 shares of Company stock on September 25, 2013 at prices ranging from (3) \$293.49 to \$294.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 25, 2013 at each separate price.
- Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 25, 2013 at prices ranging from (4) \$294.60 to \$295.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 25, 2013 at each separate price.
- (5) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

 Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3